Albert David Ltd (ALBERTDAVD) AI Stock Analysis

Albert David Ltd

(NSE:ALBERTDAVD)

Select Model

Rating:52Neutral

Price Target:INR 908.00▲(18.16% Upside)

Action:reiterated

Date:08/17/26

Albert David Ltd receives an overall score of 52, reflecting a mixed outlook. The company's financial performance is weak, with declining revenue and profitability, though a strong balance sheet mitigates immediate risk. The stock's technical picture is bullish, with price above all key moving averages, but overbought conditions suggest caution. Valuation is slightly overvalued. Investors should monitor the company's ability to restore earnings growth.

Positive Factors

Conservative Balance SheetLow leverage reduces refinancing pressure and preserves financial flexibility for operations or investment. This provides resilience during pharmaceutical pricing, regulatory, or demand disruptions, although current returns on equity have weakened.

Negative Factors

Profitability Turned NegativeThe shift from solid profits to a net and operating loss signals material margin pressure or higher costs. If persistent, weaker profitability can reduce reinvestment capacity and undermine the value of the company’s expanded asset base.

Albert David Ltd (ALBERTDAVD) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 4.35B
Dividend Yield: 0.65%
Average Volume (3M): 858
Price to Earnings (P/E): 19.3
Beta (1Y): 1.18
Revenue Growth: 11.43%
EPS Growth: 258.53%
Country: India
Employees: 1,476
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Albert David Ltd Business Overview & Revenue Model

Company Description

Albert David Limited is an Indian pharmaceutical company specializing in the production and distribution of a diverse array of medical products. Its offerings encompass pharmaceutical formulations, intravenous solutions, herbal medicines, bulk drug s...

How the Company Makes Money

Albert David Ltd primarily makes money by selling pharmaceutical products it manufactures and/or markets. Key revenue streams include: (1) Domestic sales of finished-dose formulations (e.g., tablets, capsules, syrups/other dosage forms) to hospitals,...

Albert David Ltd Financial Statement Overview

Summary

Revenue decline and margin compression led to operating and net losses, while cash flow turned negative. However, the balance sheet remains strong with low debt and high equity, providing a cushion. Overall financial health is weak but supported by solid financial position.

Income Statement

28Negative

Balance Sheet

82Very Positive

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	3.64B	3.34B	3.46B	3.60B	3.42B	3.12B
Gross Profit	1.30B	1.07B	2.29B	2.32B	2.18B	1.95B
EBITDA	-2.27M	129.20M	30.26M	1.05B	598.68M	567.76M
Net Income	225.66M	-14.95M	172.01M	754.20M	361.75M	352.58M
Balance Sheet
Total Assets	0	5.19B	5.11B	4.98B	4.23B	4.03B
Cash, Cash Equivalents and Short-Term Investments	2.58B	2.58B	2.44B	2.85B	2.03B	1.75B
Total Debt	0	297.11M	123.17M	33.24M	53.18M	56.62M
Total Liabilities	-3.92B	1.28B	1.19B	1.15B	1.12B	1.23B
Stockholders Equity	3.92B	3.92B	3.92B	3.83B	3.12B	2.79B
Cash Flow
Free Cash Flow	-271.21M	-350.95M	-432.92M	346.28M	52.78M	292.83M
Operating Cash Flow	-208.45M	-59.83M	-284.36M	455.02M	105.15M	403.65M
Investing Cash Flow	-46.97M	-85.53M	233.01M	-332.48M	-49.95M	-396.97M
Financing Cash Flow	248.82M	144.00M	1.10M	-82.70M	-63.62M	-12.59M

Albert David Ltd Technical Analysis

Technical Analysis SentimentNegative

Last Price768.45

Price Trends

50DMA835.90Negative

100DMA775.15Negative

200DMA738.01Positive

Market Momentum

MACD-19.30Positive

RSI39.84Neutral

STOCH15.29Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 768.45 is below the 20-day moving average (MA) of 794.18, below the 50-day MA of 835.90, and above the 200-day MA of 738.01, indicating a neutral trend. The MACD of -19.30 indicates Positive momentum. The RSI at 39.84 is Neutral, neither overbought nor oversold. The STOCH value of 15.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.

Albert David Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ALBERTDAVD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:GLENMARK	79Outperform	INR 651.37B	36.08	―	0.22%	32.94%	138.54%
IN:IOLCP	72Outperform	INR 52.17B	31.06	―	0.56%	18.56%	60.06%
IN:IPCALAB	71Outperform	INR 488.98B	37.34	―	0.31%	10.59%	68.21%
IN:APLLTD	70Outperform	INR 156.82B	22.62	―	1.50%	14.12%	14.98%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ALBERTDAVD	52Neutral	INR 4.35B	19.29	―	0.65%	11.43%	258.53%
IN:UNICHEMLAB	51Neutral	INR 34.04B	11.17	―	―	9.43%	132.94%

* General Sector Average

Performance Comparison

IN:ALBERTDAVD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ALBERTDAVD	Albert David Ltd	774.80	-91.80	-10.59%
IN:APLLTD	Alembic Pharmaceuticals Limited	801.20	-144.82	-15.31%
IN:GLENMARK	Glenmark Pharmaceuticals Limited	2388.00	543.18	29.44%
IN:IOLCP	IOL Chemicals & Pharmaceuticals Ltd.	180.45	88.82	96.94%
IN:IPCALAB	IPCA Laboratories Limited	1950.00	659.13	51.06%
IN:UNICHEMLAB	Unichem Laboratories Limited	504.15	33.70	7.16%

Albert David Ltd Corporate Events

Albert David publishes Q1 FY2026 unaudited results in newspapers

Aug 7, 2026

Albert David Ltd has notified the stock exchanges that it has published extracts of its unaudited financial results for the first quarter ended June 30, 2026 in national and regional newspapers. The disclosure, made in compliance with SEBI’s li...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026

Albert David Ltd AI Stock Analysis